Eupraxia Pharmaceuticals Inc. (EPRX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
EPRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Eupraxia Pharmaceuticals Inc. (EPRX) trades at a price-to-earnings ratio of -7.1x, with a stock price of $7.45 and trailing twelve-month earnings per share of $-0.91.
Compared to the Healthcare sector median P/E of 22.2x, EPRX trades at a 132% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, EPRX trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EPRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EPRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $688M | 28.1 | - | - | |
| $911M | 144.7 | - | +107%Best | |
| $8B | 25.0 | 1.09 | -25% | |
| $146B | 18.9 | - | -4% | |
| $275B | 15.3Lowest | 0.72Best | +8% | |
| $533B | 38.2 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See EPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEPRX — Frequently Asked Questions
Quick answers to the most common questions about buying EPRX stock.
Is EPRX stock overvalued or undervalued?
EPRX current P/E: -7.1x. 5-year average P/E: N/A. Percentile: N/A.
How does EPRX's valuation compare to peers?
Eupraxia Pharmaceuticals Inc. P/E of -7.1x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is EPRX's PEG ratio?
EPRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.